The conduct of in vitro and in vivo drug-drug interaction studies

A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

Thorir D. Bjornsson, John Callaghan, Heidi J. Einolf, Volker Fischer, Lawrence Gan, Scott Grimm, John Kao, S. Peter King, Gerald Miwa, Lan Ni, Gondi Kumar, James McLeod, R. Scott Obach, Stanley Roberts, Amy Roe, Anita Shah, Fred Snikeris, John T. Sullivan, Donald Tweedie, Jose M. Vega & 2 others John Walsh, Steven A. Wrighton

Research output: Contribution to journalArticle

607 Citations (Scopus)

Abstract

Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies. There is a common desire by regulatory authorities and by industry sponsors to harmonize approaches, to allow for a better assessment of the significance of findings across different studies and drugs. There is also a growing consensus for the standardization of cytochrome P450 (P450) probe substrates, inhibitors and inducers and for the development of classification systems to improve the communication of risk to health care providers and to patients. While existing guidances cover mainly P450-mediated drug interactions, the importance of other mechanisms, such as transporters, has been recognized more recently, and should also be addressed. This article was prepared by the Pharmaceutical Research and Manufacturers of America (PhRMA) Technical Working Groups and represents the current industry position. The intent is to define a minimal best practice for in vitro and in vivo pharmacokinetic drug-drug interaction studies targeted to development (not discovery support) and to define a data package that can be expected by regulatory agencies in compound registration dossiers.

Original languageEnglish (US)
Pages (from-to)815-832
Number of pages18
JournalDrug Metabolism and Disposition
Volume31
Issue number7
DOIs
StatePublished - Jul 1 2003

Fingerprint

Drug interactions
Drug Interactions
Industry
Pharmaceutical Preparations
Practice Guidelines
Health Personnel
Cytochrome P-450 Enzyme System
Pharmacokinetics
Consensus
Communication
Health care
Standardization
Pharmaceutical Research
In Vitro Techniques
Substrates

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

The conduct of in vitro and in vivo drug-drug interaction studies : A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. / Bjornsson, Thorir D.; Callaghan, John; Einolf, Heidi J.; Fischer, Volker; Gan, Lawrence; Grimm, Scott; Kao, John; King, S. Peter; Miwa, Gerald; Ni, Lan; Kumar, Gondi; McLeod, James; Obach, R. Scott; Roberts, Stanley; Roe, Amy; Shah, Anita; Snikeris, Fred; Sullivan, John T.; Tweedie, Donald; Vega, Jose M.; Walsh, John; Wrighton, Steven A.

In: Drug Metabolism and Disposition, Vol. 31, No. 7, 01.07.2003, p. 815-832.

Research output: Contribution to journalArticle

Bjornsson, TD, Callaghan, J, Einolf, HJ, Fischer, V, Gan, L, Grimm, S, Kao, J, King, SP, Miwa, G, Ni, L, Kumar, G, McLeod, J, Obach, RS, Roberts, S, Roe, A, Shah, A, Snikeris, F, Sullivan, JT, Tweedie, D, Vega, JM, Walsh, J & Wrighton, SA 2003, 'The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective', Drug Metabolism and Disposition, vol. 31, no. 7, pp. 815-832. https://doi.org/10.1124/dmd.31.7.815
Bjornsson, Thorir D. ; Callaghan, John ; Einolf, Heidi J. ; Fischer, Volker ; Gan, Lawrence ; Grimm, Scott ; Kao, John ; King, S. Peter ; Miwa, Gerald ; Ni, Lan ; Kumar, Gondi ; McLeod, James ; Obach, R. Scott ; Roberts, Stanley ; Roe, Amy ; Shah, Anita ; Snikeris, Fred ; Sullivan, John T. ; Tweedie, Donald ; Vega, Jose M. ; Walsh, John ; Wrighton, Steven A. / The conduct of in vitro and in vivo drug-drug interaction studies : A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. In: Drug Metabolism and Disposition. 2003 ; Vol. 31, No. 7. pp. 815-832.
@article{78e857e4f1f24daf8aefe2baefae00a8,
title = "The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective",
abstract = "Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies. There is a common desire by regulatory authorities and by industry sponsors to harmonize approaches, to allow for a better assessment of the significance of findings across different studies and drugs. There is also a growing consensus for the standardization of cytochrome P450 (P450) probe substrates, inhibitors and inducers and for the development of classification systems to improve the communication of risk to health care providers and to patients. While existing guidances cover mainly P450-mediated drug interactions, the importance of other mechanisms, such as transporters, has been recognized more recently, and should also be addressed. This article was prepared by the Pharmaceutical Research and Manufacturers of America (PhRMA) Technical Working Groups and represents the current industry position. The intent is to define a minimal best practice for in vitro and in vivo pharmacokinetic drug-drug interaction studies targeted to development (not discovery support) and to define a data package that can be expected by regulatory agencies in compound registration dossiers.",
author = "Bjornsson, {Thorir D.} and John Callaghan and Einolf, {Heidi J.} and Volker Fischer and Lawrence Gan and Scott Grimm and John Kao and King, {S. Peter} and Gerald Miwa and Lan Ni and Gondi Kumar and James McLeod and Obach, {R. Scott} and Stanley Roberts and Amy Roe and Anita Shah and Fred Snikeris and Sullivan, {John T.} and Donald Tweedie and Vega, {Jose M.} and John Walsh and Wrighton, {Steven A.}",
year = "2003",
month = "7",
day = "1",
doi = "10.1124/dmd.31.7.815",
language = "English (US)",
volume = "31",
pages = "815--832",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "7",

}

TY - JOUR

T1 - The conduct of in vitro and in vivo drug-drug interaction studies

T2 - A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

AU - Bjornsson, Thorir D.

AU - Callaghan, John

AU - Einolf, Heidi J.

AU - Fischer, Volker

AU - Gan, Lawrence

AU - Grimm, Scott

AU - Kao, John

AU - King, S. Peter

AU - Miwa, Gerald

AU - Ni, Lan

AU - Kumar, Gondi

AU - McLeod, James

AU - Obach, R. Scott

AU - Roberts, Stanley

AU - Roe, Amy

AU - Shah, Anita

AU - Snikeris, Fred

AU - Sullivan, John T.

AU - Tweedie, Donald

AU - Vega, Jose M.

AU - Walsh, John

AU - Wrighton, Steven A.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies. There is a common desire by regulatory authorities and by industry sponsors to harmonize approaches, to allow for a better assessment of the significance of findings across different studies and drugs. There is also a growing consensus for the standardization of cytochrome P450 (P450) probe substrates, inhibitors and inducers and for the development of classification systems to improve the communication of risk to health care providers and to patients. While existing guidances cover mainly P450-mediated drug interactions, the importance of other mechanisms, such as transporters, has been recognized more recently, and should also be addressed. This article was prepared by the Pharmaceutical Research and Manufacturers of America (PhRMA) Technical Working Groups and represents the current industry position. The intent is to define a minimal best practice for in vitro and in vivo pharmacokinetic drug-drug interaction studies targeted to development (not discovery support) and to define a data package that can be expected by regulatory agencies in compound registration dossiers.

AB - Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies. There is a common desire by regulatory authorities and by industry sponsors to harmonize approaches, to allow for a better assessment of the significance of findings across different studies and drugs. There is also a growing consensus for the standardization of cytochrome P450 (P450) probe substrates, inhibitors and inducers and for the development of classification systems to improve the communication of risk to health care providers and to patients. While existing guidances cover mainly P450-mediated drug interactions, the importance of other mechanisms, such as transporters, has been recognized more recently, and should also be addressed. This article was prepared by the Pharmaceutical Research and Manufacturers of America (PhRMA) Technical Working Groups and represents the current industry position. The intent is to define a minimal best practice for in vitro and in vivo pharmacokinetic drug-drug interaction studies targeted to development (not discovery support) and to define a data package that can be expected by regulatory agencies in compound registration dossiers.

UR - http://www.scopus.com/inward/record.url?scp=10744232330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744232330&partnerID=8YFLogxK

U2 - 10.1124/dmd.31.7.815

DO - 10.1124/dmd.31.7.815

M3 - Article

VL - 31

SP - 815

EP - 832

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 7

ER -